(Q34152326)

31 July 2017

title

Sustained viral response in a hepatitis C virus-infected chimpanzee via a combination of direct-acting antiviral agents (English)

1 reference

31 July 2017

1 reference

0 references

1 reference

David B Olsen

1

1 reference

31 July 2017

Mary-Ellen Davies

2

1 reference

31 July 2017

Larry Handt

3

1 reference

31 July 2017

Kenneth Koeplinger

4

1 reference

31 July 2017

Nanyan Rena Zhang

5

1 reference

31 July 2017

Steven W Ludmerer

6

1 reference

31 July 2017

Donald Graham

7

1 reference

31 July 2017

Nigel Liverton

8

1 reference

31 July 2017

Malcolm MacCoss

9

1 reference

31 July 2017

Daria Hazuda

10

1 reference

31 July 2017

Steven S Carroll

11

1 reference

31 July 2017

language of work or name

English

0 references

publication date

29 November 2010

1 reference

Antimicrobial Agents and Chemotherapy

31 July 2017

published in

1 reference

31 July 2017

volume

55

1 reference

31 July 2017

issue

2

1 reference

31 July 2017

page(s)

937-939

1 reference

MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A Protease

31 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3028818

Robust Antiviral Efficacy upon Administration of a Nucleoside Analog to Hepatitis C Virus-Infected Chimpanzees

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3028818

A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3028818

Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3028818

Side effects of therapy of hepatitis C and their management

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3028818

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3028818

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3028818

Relapse of hepatitis C in a pegylated-interferon-alpha-2b plus ribavirin-treated sustained virological responder

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3028818

A transient cell-based phenotype assay for hepatitis C NS3/4A protease: application to potency determinations of a novel macrocyclic inhibitor against diverse protease sequences isolated from plasma infected with HCV.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3028818

28 October 2018

Identifiers

DOI

10.1128/AAC.00990-10

1 reference

31 July 2017

1 reference

31 July 2017

1 reference